T-cell lymphoma market predicted to be worth $1.8 billion by 2030

11 May 2022

The market for T-cell lymphomas (TCLs) – a rare type of the blood cancer group of non-Hodgkin’s lymphomas – is expected to see strong growth at a 6.4% compound annual growth rate (CAGR) over the next decade in the world’s eight major markets (8MM).

This is the view of data and insights provider GlobalData, which anticipates that the numerous drugs currently in late-stage clinical trials will reach the market and drive the forecast growth.

"Among the most important unmet needs are better systemic treatment for cutaneous TCL"However, GlobalData notes that this growth would have been a lot higher if there was a more industrial focus on the relatively neglected cutaneous TCL subtype.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK